Management of Aneurysmal Subarachnoid Hemorrhage with Nimodipine

Introduction to Nimodipine Therapy

• Early initiation of enteral nimodipine (60 mg every 4 hours for 21 days) is strongly recommended in all patients with aneurysmal subarachnoid hemorrhage (aSAH) to prevent delayed cerebral ischemia (DCI) and improve functional outcomes, as recommended by the American Heart Association 1, 2

Mechanism and Evidence

• Nimodipine works by preventing DCI through mechanisms beyond simply reversing large vessel vasospasm, likely including neuroprotective effects, according to the American Stroke Association 2, 3
• A meta-analysis of 16 trials involving 3361 patients confirmed nimodipine's benefit in preventing DCI and improving functional outcomes, with a strong level of evidence 2

Administration Protocol

• Nimodipine should be administered enterally at a dose of 60 mg every 4 hours for 21 consecutive days, as recommended by the American College of Cardiology 2, 4
• Treatment should begin within 96 hours of hemorrhage onset, with consistent administration being critical to prevent DCI 4
• Disruption of nimodipine therapy has been associated with a greater incidence of DCI (ρ=0.431, P<0.001), highlighting the importance of maintaining full dosing 2

Management of Side Effects

• In cases of nimodipine-induced hypotension, standard medical interventions to maintain blood pressure should be attempted before reducing the dose, as suggested by the American Heart Association 2
• If nimodipine causes significant blood pressure variability that cannot be managed, temporary dose reduction or interruption may be necessary, according to the American Stroke Association 2

Integration with Other Treatments

• Nimodipine should be used alongside other standard treatments for aSAH, including maintaining euvolemia to prevent DCI, as recommended by the American College of Cardiology 1, 2, 4
• For patients who develop symptomatic vasospasm despite nimodipine therapy, additional interventions may include elevation of systolic blood pressure, intra-arterial vasodilator therapy, and cerebral angioplasty, according to the American Heart Association 2